Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Faculty of Medicine, Oita University | Japan

Author Profile 

Scopus

🧬 Dr. Haruto Nishida, M.D., Ph.D. – Associate Professor of Diagnostic Pathology

Haruto Nishida, M.D., Ph.D., is an Associate Professor at the Department of Diagnostic Pathology at Oita University Hospital, Japan, where he has served in this role since April 2021. Dr. Nishida has a profound expertise in pathology, with a particular focus on diagnostic pathology, cytology, and molecular pathology.

🎓 Education and Early Career

Dr. Nishida earned his Medical Degree from the Faculty of Medicine at Oita University in 2009. He furthered his academic journey by obtaining a Ph.D. from the same institution in 2015, specializing in pathology. His post-graduate training includes a residency in General Medicine at Oita Medical Hospital and a fellowship in Diagnostic Pathology at Oita University.

🩺 Professional Experience

Dr. Nishida’s career at Oita University has been marked by progressive roles. Starting as an Assistant Professor in 2012, he was promoted to Lecturer in 2019 and then to Associate Professor in 2020. He continued in this role when he transitioned to Oita University Hospital in 2021, where he currently leads efforts in diagnostic pathology.

🏅 Board Certifications and Licensure

Dr. Nishida holds multiple prestigious board certifications, including the Japanese Board Certification in Pathology, Autopsy, Cytology, and Molecular Pathology. He earned his National Board of Medicine license in 2009, showcasing his dedication to the field.

🌍 Professional Affiliations

Dr. Nishida is an active member of several professional organizations, both in Japan and internationally. He is involved with the Japanese Society of Pathology, Japanese Society of Clinical Cytology, Japan Dermatopathology Society, and the Bone and Soft Tissue Tumor Club of Japan. Additionally, he is a member of the United States and Canadian Academy of Pathology (USCAP) and the International Academy of Cytology.

Dr. Nishida’s contributions to the field of pathology, combined with his ongoing research and teaching, make him a distinguished figure in diagnostic pathology.

🚀 Conclusion

In summary, Dr. Haruto Nishida is a highly accomplished pathologist whose extensive expertise and dedication to diagnostic pathology have significantly contributed to the field. His career, marked by a progression of academic and clinical roles at Oita University, is underpinned by his strong educational background and numerous board certifications. As an active member of both national and international professional organizations, Dr. Nishida continues to impact the field through his research, teaching, and clinical work. His ongoing commitment to excellence in pathology makes him a respected leader in the medical community.

 

📊🔬NOTABLE PUBLICATION:

 

  • SOX10-Internal Tandem Duplications and PLAG1 or HMGA2 Fusions Segregate Eccrine-Type and Apocrine-Type Cutaneous Mixed Tumors
    Authors: Macagno, N., Kervarrec, T., Thanguturi, S., De la Fouchardière, A., Battistella, M.
    Journal: Modern Pathology
    Year: 2024

 

  • Recurrent Cardiac Tamponade Following Coronavirus Disease 2019 mRNA Vaccination: A Case Report
    Authors: Kaimori, R., Nishida, H., Yahiro, T., Iwami, T., Daa, T.
  • Journal: Cardiovascular Pathology
    Year: 2024

 

  • Lipid Droplet Detection in Histopathological Images Using Reinforcement Learning
    Authors: Harada, Y., Nishida, H., Matsuura, K.
    Journal: Biotechnology and Biotechnological Equipment
    Year: 2024

 

  • Right Atrial Cardiac Myxoma with Malignant Transformation to Undifferentiated Sarcoma: A Case Report
    Authors: Kaimori, R., Nishida, H., Oyama, Y., Kawamura, K., Daa, T.
    Journal: Cardiovascular Pathology
    Year: 2024

 

  • The Relationship Between Tumor Immunity and the cGAS–STING Pathway in Breast Cancer: An Immunohistochemical Study
    Authors: Nishida, H., Ohara, N., Kato, A., Kawamura, K., Daa, T.
    Journal: Experimental and Molecular Pathology
    Year: 2024

Prof Shengping Hou | Immunotherapy | Best Researcher Award

Prof Shengping Hou | Immunotherapy | Best Researcher Award

Beijing Tongren Hospital, Capital Medical University | China

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

Shengping Hou, Ph.D., began his academic journey at Sun Yat-sen University in China, where he obtained his Ph.D. in Ocular Immunology in 2009. His doctoral research laid the foundation for his future contributions to ocular immunology, particularly focusing on the genetic aspects of ocular diseases. Following his Ph.D., Dr. Hou furthered his expertise with a postdoctoral fellowship at the University of California, San Francisco, specializing in Ocular Stem Cell Biology, which he completed in 2016.

PROFESSIONAL ENDEAVORS

Dr. Hou’s professional career commenced at The First Affiliated Hospital of Chongqing Medical University, where he served as an Associate Professor from 2009 to 2015. He was later promoted to Professor, a position he held until 2023. During his tenure, he was also a key figure at the Chongqing Key Laboratory of Ophthalmology. In 2023, Dr. Hou transitioned to Beijing Tongren Hospital, where he now serves as the Director of the Beijing Institute of Ophthalmology and continues his professorship at Capital Medical University.

CONTRIBUTIONS AND RESEARCH FOCUS ON IMMUNOTHERAPY

Dr. Hou’s research has primarily centered on the genetic and immunological underpinnings of ocular diseases, particularly uveitis and Behcet’s disease. His work has involved extensive genetic studies, including the investigation of VKH syndrome and the role of complement component 4 copy number variants in ocular pathogenesis. His notable projects have been consistently supported by grants from the National Natural Science Foundation and other key R&D initiatives in China.

IMPACT AND INFLUENCE

Dr. Hou’s contributions have earned him significant recognition in the scientific community. He has been honored with several prestigious awards, including the First Prize for Achievement in Science and Technology from both Chongqing and the Chinese Health Ministry. His research findings have been widely disseminated through invited lectures and presentations at major international conferences, enhancing the understanding of genetic influences in ocular diseases.

ACADEMIC CITATIONS

Throughout his career, Dr. Hou has been an active member of the Chinese Ocular Immunology Society and has served as an ad hoc reviewer for several high-impact journals such as Nature Reviews Rheumatology, Advanced Science, and eBioMedicine. His work has been extensively cited by peers, reflecting the significant impact of his research on the field of ocular immunology.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Hou’s legacy in the field of ophthalmology is marked by his dedication to uncovering the genetic mechanisms underlying ocular diseases. As the Director of the Beijing Institute of Ophthalmology, he continues to lead groundbreaking research and mentor the next generation of scientists. His future contributions are poised to further advance the understanding and treatment of ocular conditions, solidifying his status as a leading figure in ophthalmic research.

NOTABLE PUBLICATION: